Novo Nordisk to Pay Up to $2 Billion to License Chinese Company’s Weight-Loss Drug
Novo Nordisk said Monday that it had entered into a license agreement with a Chinese company developing a competitor to ...
Will the Mounjaro weight-loss drug reshape the Indian stock markets? Nithin Kamath says ‘people will trade less’
Mounjaro, a newly launched weight-loss and diabetes drug, is now available in India. Developed by Eli Lilly, it promises more effectiveness than Ozempic and comes at a lower cost. Experts believe it ...
pharmaphorum6m
Novo Nordisk looks east for another obesity therapy
Novo Nordisk already has a fairly well-stocked pipeline of candidates, but one of its near-term hopes – CagriSema, which combines semaglutide with dual amylin and calcitonin receptor agonist ...
The Manila Times29m
Sesame, America's Low-Cost Leader in Healthcare, Streamlines Access for Eligible Patients to Lilly's Obesity Medicine Zepbound
Streamlined access to authentic, FDA-approved, rigorously-tested Zepbound comes from Sesame's direct integration with Gifthealth. Zepbound is the first and only FDA-approved dual glucagon-like peptide ...